Can you take Armodafinil with Gepirone?

Armodafinil has a moderate potential interaction with Alcoholism.

Patients with excessive sleepiness, including those taking armodafinil, should be frequently reassessed for their degree of sleepiness and, if appropriate, advised to avoid driving or any other potentially dangerous activity. Patients should refrain from drinking alcohol while taking armodafinil as any drug affecting the central nervous system (CNS) may alter judgment, thinking or motor skills.

Gepirone has a major potential interaction with Bipolar Disorder.

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older. Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide. Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes. Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider. Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.

Gepirone has a moderate potential interaction with Bipolar Disorder.

All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder. Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.

Gepirone has a major potential interaction with Cardiovascular Conditions and Disorders.

This drug prolongs the QT interval. Use of gepirone in patients with congenital long QT syndrome is contraindicated. Treatment is also contraindicated in patients with severe hepatic impairment or in patients receiving concomitant strong CYP450 3A4 inhibitors because plasma drug concentrations may be increased in these population. Gepirone should not be initiated in patients with baseline QTc greater than 450 msec, and the dosage of gepirone should not be escalated if the QTcF is greater than 450 msec. Electrolyte abnormalities should be corrected prior to starting treatment, and then monitored during dose titration and periodically during treatment in patients with electrolyte abnormalities, or who are receiving diuretics or glucocorticoids, or who have a history of hypokalemia or hypomagnesemia. An electrocardiogram (ECG) should be performed prior to initiating therapy, during dosage titration, and periodically during treatment. Monitor patients with ECGs more frequently if gepirone is used concomitantly with drugs known to prolong the QT interval, in patients who develop a QTc of 450 msec or greater during treatment, or in patients with a significant risk of developing torsade de pointes, including those with uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, uncontrolled hypertension, high-degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism. Reduce the dose of this drug when used concomitantly with moderate CYP3A4 inhibitors, as they may increase drug concentrations.

Armodafinil has a moderate potential interaction with Cardiovascular Conditions and Disorders.

Armodafinil may cause ECG changes, chest pain, or arrhythmia. Armodafinil should be used with caution in patients with cardiovascular complications. Armodafinil should not be used in patients with a history of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants. It is recommended to monitor heart rate and blood pressure during treatment with armodafinil. Caution should be exercised when prescribing armodafinil to patients with known cardiovascular disease.

Armodafinil has a major potential interaction with Depression.

The use of CNS stimulants can cause psychotic symptoms, suicidal ideation, and aggression, and can exacerbate symptoms of behavior disturbance and thought disorder; CNS stimulants may induce a manic or mixed episode in patients with bipolar disorder. Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders. All patients (particularly those with psychotic or bipolar disorders) should be monitored closely, especially during treatment initiation and at times of dose changes. Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder. Prior to initiating therapy, all patients should be screened for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or family history of suicide, bipolar disease, or depression). If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered. Some CNS stimulants are contraindicated in patients with marked agitation or anxiety.

Gepirone has a major potential interaction with Depression.

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older. Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide. Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes. Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider. Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.

Armodafinil has a moderate potential interaction with Depression.

Armodafinil may cause adverse psychiatric reactions. Caution should be exercised when using this agent in patients with a history of psychosis, depression, or mania. If psychiatric symptoms develop in association with armodafinil administration, consider discontinuing armodafinil. Close monitoring of psychiatric symptoms is recommended.

Gepirone has a major potential interaction with Heart Disease.

This drug prolongs the QT interval. Use of gepirone in patients with congenital long QT syndrome is contraindicated. Treatment is also contraindicated in patients with severe hepatic impairment or in patients receiving concomitant strong CYP450 3A4 inhibitors because plasma drug concentrations may be increased in these population. Gepirone should not be initiated in patients with baseline QTc greater than 450 msec, and the dosage of gepirone should not be escalated if the QTcF is greater than 450 msec. Electrolyte abnormalities should be corrected prior to starting treatment, and then monitored during dose titration and periodically during treatment in patients with electrolyte abnormalities, or who are receiving diuretics or glucocorticoids, or who have a history of hypokalemia or hypomagnesemia. An electrocardiogram (ECG) should be performed prior to initiating therapy, during dosage titration, and periodically during treatment. Monitor patients with ECGs more frequently if gepirone is used concomitantly with drugs known to prolong the QT interval, in patients who develop a QTc of 450 msec or greater during treatment, or in patients with a significant risk of developing torsade de pointes, including those with uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, uncontrolled hypertension, high-degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism. Reduce the dose of this drug when used concomitantly with moderate CYP3A4 inhibitors, as they may increase drug concentrations.

Gepirone has a major potential interaction with Heart Failure.

This drug prolongs the QT interval. Use of gepirone in patients with congenital long QT syndrome is contraindicated. Treatment is also contraindicated in patients with severe hepatic impairment or in patients receiving concomitant strong CYP450 3A4 inhibitors because plasma drug concentrations may be increased in these population. Gepirone should not be initiated in patients with baseline QTc greater than 450 msec, and the dosage of gepirone should not be escalated if the QTcF is greater than 450 msec. Electrolyte abnormalities should be corrected prior to starting treatment, and then monitored during dose titration and periodically during treatment in patients with electrolyte abnormalities, or who are receiving diuretics or glucocorticoids, or who have a history of hypokalemia or hypomagnesemia. An electrocardiogram (ECG) should be performed prior to initiating therapy, during dosage titration, and periodically during treatment. Monitor patients with ECGs more frequently if gepirone is used concomitantly with drugs known to prolong the QT interval, in patients who develop a QTc of 450 msec or greater during treatment, or in patients with a significant risk of developing torsade de pointes, including those with uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, uncontrolled hypertension, high-degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism. Reduce the dose of this drug when used concomitantly with moderate CYP3A4 inhibitors, as they may increase drug concentrations.

Gepirone has a major potential interaction with Hypokalemia.

This drug prolongs the QT interval. Use of gepirone in patients with congenital long QT syndrome is contraindicated. Treatment is also contraindicated in patients with severe hepatic impairment or in patients receiving concomitant strong CYP450 3A4 inhibitors because plasma drug concentrations may be increased in these population. Gepirone should not be initiated in patients with baseline QTc greater than 450 msec, and the dosage of gepirone should not be escalated if the QTcF is greater than 450 msec. Electrolyte abnormalities should be corrected prior to starting treatment, and then monitored during dose titration and periodically during treatment in patients with electrolyte abnormalities, or who are receiving diuretics or glucocorticoids, or who have a history of hypokalemia or hypomagnesemia. An electrocardiogram (ECG) should be performed prior to initiating therapy, during dosage titration, and periodically during treatment. Monitor patients with ECGs more frequently if gepirone is used concomitantly with drugs known to prolong the QT interval, in patients who develop a QTc of 450 msec or greater during treatment, or in patients with a significant risk of developing torsade de pointes, including those with uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, uncontrolled hypertension, high-degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism. Reduce the dose of this drug when used concomitantly with moderate CYP3A4 inhibitors, as they may increase drug concentrations.

Gepirone has a major potential interaction with Liver Disease.

Exposure to gepirone is increased in patients with hepatic impairment. Use of gepirone in patients with severe hepatic impairment (Child-Pugh C) is contraindicated. A dose reduction is recommended in patients with moderate hepatic impairment (Child-Pugh B). No dosage adjustment is recommended patients with mild hepatic impairment (Child-Pugh A).

Armodafinil has a moderate potential interaction with Liver Disease.

In a study to determine the pharmacokinetics and metabolism of armodafinil in patients with cirrhosis, the oral clearance of armodafinil was decreased by about 60%, and the steady state concentration was doubled compared to healthy patients. The dosage of armodafinil should be reduced in patients with severe hepatic impairment. Close monitoring is recommended.

Gepirone has a major potential interaction with Long QT Syndrome.

This drug prolongs the QT interval. Use of gepirone in patients with congenital long QT syndrome is contraindicated. Treatment is also contraindicated in patients with severe hepatic impairment or in patients receiving concomitant strong CYP450 3A4 inhibitors because plasma drug concentrations may be increased in these population. Gepirone should not be initiated in patients with baseline QTc greater than 450 msec, and the dosage of gepirone should not be escalated if the QTcF is greater than 450 msec. Electrolyte abnormalities should be corrected prior to starting treatment, and then monitored during dose titration and periodically during treatment in patients with electrolyte abnormalities, or who are receiving diuretics or glucocorticoids, or who have a history of hypokalemia or hypomagnesemia. An electrocardiogram (ECG) should be performed prior to initiating therapy, during dosage titration, and periodically during treatment. Monitor patients with ECGs more frequently if gepirone is used concomitantly with drugs known to prolong the QT interval, in patients who develop a QTc of 450 msec or greater during treatment, or in patients with a significant risk of developing torsade de pointes, including those with uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, uncontrolled hypertension, high-degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism. Reduce the dose of this drug when used concomitantly with moderate CYP3A4 inhibitors, as they may increase drug concentrations.

Gepirone has a major potential interaction with Magnesium Imbalance.

This drug prolongs the QT interval. Use of gepirone in patients with congenital long QT syndrome is contraindicated. Treatment is also contraindicated in patients with severe hepatic impairment or in patients receiving concomitant strong CYP450 3A4 inhibitors because plasma drug concentrations may be increased in these population. Gepirone should not be initiated in patients with baseline QTc greater than 450 msec, and the dosage of gepirone should not be escalated if the QTcF is greater than 450 msec. Electrolyte abnormalities should be corrected prior to starting treatment, and then monitored during dose titration and periodically during treatment in patients with electrolyte abnormalities, or who are receiving diuretics or glucocorticoids, or who have a history of hypokalemia or hypomagnesemia. An electrocardiogram (ECG) should be performed prior to initiating therapy, during dosage titration, and periodically during treatment. Monitor patients with ECGs more frequently if gepirone is used concomitantly with drugs known to prolong the QT interval, in patients who develop a QTc of 450 msec or greater during treatment, or in patients with a significant risk of developing torsade de pointes, including those with uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, uncontrolled hypertension, high-degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism. Reduce the dose of this drug when used concomitantly with moderate CYP3A4 inhibitors, as they may increase drug concentrations.

Gepirone has a moderate potential interaction with Mania.

All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder. Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.

Armodafinil has a major potential interaction with Psychosis.

The use of CNS stimulants can cause psychotic symptoms, suicidal ideation, and aggression, and can exacerbate symptoms of behavior disturbance and thought disorder; CNS stimulants may induce a manic or mixed episode in patients with bipolar disorder. Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders. All patients (particularly those with psychotic or bipolar disorders) should be monitored closely, especially during treatment initiation and at times of dose changes. Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder. Prior to initiating therapy, all patients should be screened for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or family history of suicide, bipolar disease, or depression). If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered. Some CNS stimulants are contraindicated in patients with marked agitation or anxiety.

Armodafinil has a moderate potential interaction with Psychosis.

Armodafinil may cause adverse psychiatric reactions. Caution should be exercised when using this agent in patients with a history of psychosis, depression, or mania. If psychiatric symptoms develop in association with armodafinil administration, consider discontinuing armodafinil. Close monitoring of psychiatric symptoms is recommended.

Gepirone has a moderate potential interaction with Renal Dysfunction.

Patients with renal impairment may experience reduced metabolism and excretion of gepirone. The recommended dose of gepirone in patients with CrCl less than 50 mL/min is reduced as compared to patients with normal renal function. No dosage adjustment is recommended for patients with CrCl 50 mL/min or greater.

Gepirone has a major potential interaction with Underactive Thyroid.

This drug prolongs the QT interval. Use of gepirone in patients with congenital long QT syndrome is contraindicated. Treatment is also contraindicated in patients with severe hepatic impairment or in patients receiving concomitant strong CYP450 3A4 inhibitors because plasma drug concentrations may be increased in these population. Gepirone should not be initiated in patients with baseline QTc greater than 450 msec, and the dosage of gepirone should not be escalated if the QTcF is greater than 450 msec. Electrolyte abnormalities should be corrected prior to starting treatment, and then monitored during dose titration and periodically during treatment in patients with electrolyte abnormalities, or who are receiving diuretics or glucocorticoids, or who have a history of hypokalemia or hypomagnesemia. An electrocardiogram (ECG) should be performed prior to initiating therapy, during dosage titration, and periodically during treatment. Monitor patients with ECGs more frequently if gepirone is used concomitantly with drugs known to prolong the QT interval, in patients who develop a QTc of 450 msec or greater during treatment, or in patients with a significant risk of developing torsade de pointes, including those with uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, uncontrolled hypertension, high-degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism. Reduce the dose of this drug when used concomitantly with moderate CYP3A4 inhibitors, as they may increase drug concentrations.

Armodafinil has a moderate potential interaction with Valvular Heart Disease.

Armodafinil may cause ECG changes, chest pain, or arrhythmia. Armodafinil should be used with caution in patients with cardiovascular complications. Armodafinil should not be used in patients with a history of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants. It is recommended to monitor heart rate and blood pressure during treatment with armodafinil. Caution should be exercised when prescribing armodafinil to patients with known cardiovascular disease.